You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

immunotherapy with inhibitor of PD-1/L1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Efficacy, Safety Trial (PD-L1 inhibitor)

Not yet recruiting
  • Efficacy
  • Safety
  • PD-L1 inhibitor
  • (no location specified)
Apr 6, 2022

Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral) Trial in Ljubljana (Immune

Recruiting
  • Metastatic Melanoma
  • +3 more
  • Immune checkpoint inhibitor
  • Ljubljana, Slovenia
    Institute of Oncology Ljubljana
May 17, 2023

Non Small Cell Lung Cancer Metastatic Trial (Pembrolizumab in Combination with Plinabulin and Docetaxel)

Not yet recruiting
  • Non Small Cell Lung Cancer Metastatic
  • Pembrolizumab in Combination with Plinabulin and Docetaxel
  • (no location specified)
Oct 28, 2022

Metastatic Cancer, Urothelial Carcinoma Trial (avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin)

Not yet recruiting
  • Metastatic Cancer
  • Urothelial Carcinoma
  • avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
  • (no location specified)
Dec 19, 2022

Pre-transplant ICI Exposure and Post-transplant Graft Rejection

Recruiting
  • Graft Rejection
  • +3 more
  • Immune checkpoint inhibitor
  • Guangzhou, Guangdong, China
    Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
Jun 21, 2023

Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Recruiting
  • Non Small Cell Lung Cancer
  • anti-PD-1 or anti-PD-L1
  • +2 more
  • Shanghai, China
    Oncology Department, Shanghai Chest Hospital
Jul 26, 2022

Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 Trial (Nivolumab,

Withdrawn
  • Lung Non-Small Cell Carcinoma
  • +12 more
  • (no location specified)
May 24, 2022

Breast Cancer, Triple Negative Breast Cancer Trial in Washington, Boston, Chapel Hill (Niraparib, Dostarlimab, Radiation

Recruiting
  • Breast Cancer
  • Triple Negative Breast Cancer
  • Washington, District of Columbia
  • +2 more
Apr 13, 2022

Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
    • Alton, Illinois
    • +6 more
    May 18, 2022

    Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

    Completed
    • Advanced Solid Tumor
    • Inosine 0.2g orally 3 times/day
    • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
    • Beijing, Beijing, China
      Qin li
    Mar 30, 2023

    Esophageal Tumor Metastatic, Esophageal Cancer Stage IVb Trial in Beijing (drug, biological, radiation)

    Recruiting
    • Esophageal Neoplasm Metastatic
    • Esophageal Cancer Stage IVb
    • TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
    • +3 more
    • Beijing, Beijing, China
      Cancer hospital, CAMS
    Oct 19, 2023

    Molecular Subtyping of Extensive Stage Small Cell Lung Cancer

    Recruiting
    • SCLC,Extensive Stage
    • PD-(L)1 antibody immunotherapy
    • Beijing, Beijing, China
      Peking University Cancer Hospital & Institute
    Jul 3, 2023

    Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

    Not yet recruiting
    • Lung Cancer
    • Centipeda minima+PD-1/PD-L1 inhibitor
    • PD-1/PD-L1 inhibitor
    • (no location specified)
    Feb 17, 2023

    Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

    Not yet recruiting
    • Metastatic Microsatellite-stable Colorectal Cancer
    • (no location specified)
    Sep 1, 2023

    Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

    Recruiting
    • Lung Cancer
    • Yiwu, Zhejiang, China
      The Fourth Affiliated Hospital of Zhejiang University
    Dec 16, 2022

    CX3CR1+T Cell Predict Immunotherapy Efficacy

    Recruiting
    • Non-small Cell Lung Cancer
    • PD-1 inhibitor based immunotherapy
    • Changsha, Hunan, China
    • +1 more
    Sep 19, 2023

    Small-cell Lung Cancer Trial in Shanghai (thoracic radiotherapy)

    Recruiting
    • Small-cell Lung Cancer
    • thoracic radiotherapy
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai jiaotong univestigy school of medicine
    Sep 21, 2022

    Non Small Cell Lung Cancer Recurrent Trial (Toripalimab, Anlotinib and Chemotherapy)

    Not yet recruiting
    • Non Small Cell Lung Cancer Recurrent
    • Toripalimab, Anlotinib and Chemotherapy
    • (no location specified)
    Apr 24, 2023

    Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

    Not yet recruiting
    • Metastatic Pancreatic Cancer
    • Durvalumab
    • Rintatolimod
    • Rotterdam, Zuid-Holland, Netherlands
      Erasmus MC
    Jun 23, 2023

    Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • BTK inhibitor
    • PD-1 inhibitor
    • Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    May 20, 2023

    Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

    Recruiting
    • Advanced Solid Tumor
    • Refractory Tumor
    • Radiotherapy
    • +4 more
    • Suzhou, China
      The Second Affiliated Hospital of SchoowUniversity
    Sep 14, 2023

    Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

    Recruiting
    • Advanced Solid Tumor
    • Refractory Tumor
    • Suzhou, China
      The Second Affiliated Hospital of SchoowUniversity
    Mar 29, 2023

    Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

    Not yet recruiting
    • Advanced Non Small Cell Lung Cancer
    • (no location specified)
    Oct 24, 2023

    Malignant Pleural Mesothelioma Trial in Edegem, Ghent, Sint-Niklaas (Dendritic cell vaccination, Atezolizumab,

    Not yet recruiting
    • Malignant Pleural Mesothelioma
    • Dendritic cell vaccination
    • +2 more
    • Edegem, Antwerp, Belgium
    • +2 more
    Feb 28, 2023

    Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),

    Not yet recruiting
    • Nasopharyngeal Carcinoma
    • Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
    • +3 more
    • Guangzhou, Guangdong, China
      Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
    Sep 17, 2022